Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Boston Scientific (BSX – Research Report), ANI Pharmaceuticals (ANIP – Research Report) and Merck & Company (MRK – Research Report).
Boston Scientific (BSX)
In a report issued on March 1, Marie Thibault from BTIG reiterated a Buy rating on Boston Scientific, with a price target of $72.00. The company’s shares closed last Friday at $67.13, close to its 52-week high of $67.40.
According to TipRanks.com, Thibault is a 1-star analyst with an average return of
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $68.64, which is a 3.5% upside from current levels. In a report issued on February 27, Piper Sandler also maintained a Buy rating on the stock with a $72.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ANI Pharmaceuticals (ANIP)
The company’s shares closed last Friday at $67.17, close to its 52-week high of $70.50.
According to TipRanks.com, Sulewski is a 4-star analyst with an average return of
ANI Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $39.00.
Merck & Company (MRK)
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Merck & Company on March 1 and set a price target of $130.00. The company’s shares closed last Friday at $126.96, close to its 52-week high of $130.24.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $136.35.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BSX:
- Boston Scientific receives FDA approval for Farapulse PFA System
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Boston Scientific price target raised to $70 from $60 at Barclays
- Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls
- Boston Scientific price target raised to $63 from $55 at Deutsche Bank
